PRINCETON, NJ--Cytogen Corporation is sponsoring a new website on
prostate cancer that highlights its diagnostic imaging agent
ProstaScint. The agent is used in newly diagnosed patients at high
risk for metastases and in postprostatectomy patients with a high
suspicion of recurrence or spread.
The website (www.prostascint.com)
has features for both physicians and patients. It includes full
prescribing information and assistance for physicians in selecting
the best course of treatment. It gives physicians the ability to post
scans of their cases on a password-protected teleradiology section.
This allows physicians to post images and exchange information with
colleagues for the purposes of clinical or technical discussion.
Among the sites features available to patients are the
"Medical Minute," an interactive question and answer
section; information on reimbursement and a reimbursement hotline;
access to a tutorial on prostate cancer and one of the largest,
searchable prostate cancer support group directories, giving patients
and families access to information on local meetings across the
A second website (www.cytogen.com)
offers a comprehensive look at Cytogens services, including
extensive information on Quadramet, the companys product for
the treatment of bone pain resulting from cancer that has spread to